Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 30;9(3):e0024.
doi: 10.5041/RMMJ.10345.

Evolution of Glaucoma Surgery in the Last 25 Years

Affiliations
Review

Evolution of Glaucoma Surgery in the Last 25 Years

Laura Bar-David et al. Rambam Maimonides Med J. .

Abstract

Glaucoma is a chronic neurodegenerative optic nerve disease. Treatment is intended to prevent the development and progression of optic nerve damage by lowering intraocular pressure (IOP). Current therapy options include topical/systemic drugs that increase aqueous humor outflow or decrease its production, laser therapy that targets the trabecular meshwork and ciliary body, and incisional surgery. Trabeculectomy as well as glaucoma drainage devices are often performed, given their high efficacy in lowering IOP. However, the significant risk profile with potential sight-threatening complications has motivated glaucoma experts to create alternative surgeries to treat glaucoma. Minimally invasive glaucoma surgery (MIGS) is defined by: micro-invasive approach, minimal tissue trauma, high safety profile, and rapid recovery. The new devices might promote an earlier transition from medical/laser therapy to surgery, and therefore decrease the side effects associated with long-term use of topical medications as well as deal with the limited adherence of patients to their regimens. This review presents the surgical options available for glaucoma patients and their evolution over the past 25 years.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: No potential conflict of interest relevant to this article was reported.

References

    1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010–2020. Br J Ophthalmol. 2006;90:262–7. doi: 10.1136/bjo.2005.081224. - DOI - PMC - PubMed
    1. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–79. doi: 10.1136/bjo.2005.081224. - DOI - PubMed
    1. Coleman AL. Advances in glaucoma treatment and management: surgery. Invest Opthalmol Vis Sci. 2012;53:2491. doi: 10.1136/bjo.2005.081224. - DOI - PubMed
    1. Gedde SJ, Schiffman JC, Feuer WJ, et al. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol. 2012;153:789–803.e2. doi: 10.1136/bjo.2005.081224. - DOI - PMC - PubMed
    1. Borisuth NS, Phillips B, Krupin T. The risk profile of glaucoma filtration surgery. Curr Opin Ophthalmol. 1999;10:112–16. - PubMed

LinkOut - more resources